Search

Displaying results 1651 - 1660 of 1723 in total
  1. Drug

    Mersalyl

    go.drugbank.com/drugs/DB09338
    Experimental

    It is an outdated drug, and its approval has been discontinued by the FDA. Mersalyl acid is currently replaced by less toxic non-mercury containing diuretics [L1575, L1577].

  2. Drug

    Pleconaril

    go.drugbank.com/drugs/DB05105
    Investigational

    Food and Drug Administration (FDA) due to the fact that it has been found to induce CYP3A enzyme activity, therefore increasing the risk for serious drug interactions.

  3. Drug

    Magnesium oxide

    go.drugbank.com/drugs/DB01377
    ApprovedInvestigational

    Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses.

    Mixtures: PNV 27-Ca/Fe/FA
  4. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers.

  5. Drug

    OSI-7836

    go.drugbank.com/drugs/DB05837
    Experimental

    It is also more active than ara-C (another clinically used nucleoside analog) in all nine models and more active than either paclitaxel or cisplatin in the two lung xenograft models tested.

  6. Drug

    TGAAC94

    go.drugbank.com/drugs/DB06175
    Investigational

    In 2007, one patient participating in the clinical trial died and the trial was placed on clinical hold by the FDA.

  7. Drug

    Somatrogon

    go.drugbank.com/drugs/DB14960
    ApprovedInvestigational

    [L39060] In June 2023, the FDA approved the use of somatrogon also for the treatment of pediatric growth hormone deficiency.

  8. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral

  9. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    [A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ.[L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant].

  10. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.[L8063]